AAGH 8-K
America Great Health (AAGH)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
| (Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Item 8.01. Other Events.
Clinical Observation Study of Ion-Modified Peptide Products
America Great Health (the “Company”) is providing an update regarding a clinical observation study involving ion-modified peptide products identified in the study as AX-3 (“Ion Peptide No. 1”) and PPY-3 (“Ion Peptide No. 4”).
The clinical observation study was conducted at Zhejiang Kangjing Hospital in China during the period from December 2024 through May 2026. According to the study report provided to the Company, the study evaluated the use of the ion-modified peptide products as adjunctive treatment in a total of ten subjects, consisting of eight subjects with solid tumors, one subject with malignant lymphoma, and one subject with bronchiectasis accompanied by hemoptysis.
The eight subjects with solid tumors included five subjects with lung cancer or lung cancer with metastatic disease, two subjects with colorectal cancer, and one subject with liver cancer. Certain subjects had significant underlying medical conditions or advanced disease.
The study was observational in nature and the ion-modified peptide products were administered as adjunctive treatment rather than as stand-alone cancer therapy. The solid-tumor subjects had received or were receiving other forms of treatment, including chemotherapy, radiation therapy, surgery and/or targeted therapy. Accordingly, the observed outcomes cannot be attributed solely to the ion-modified peptide products.
The hospital’s report describes observations at baseline and, where available, approximately one month, three months and six months after initiation of adjunctive treatment. The observations included clinical symptoms, vital signs, peripheral blood measurements, lipid-related measurements and certain immune-cell measurements.
According to the report, certain subjects experienced improvements in reported clinical symptoms during the observation period. The underlying patient data also reflect changes over time in certain measured parameters. The results, however, varied among subjects and across measured parameters.
Two subjects with advanced malignancies and significant underlying disease died approximately 25 days and 22 days, respectively, after beginning the observation period and were withdrawn from the study. The hospital report states that both subjects had advanced disease complicated by multiple-organ failure.
The hospital report further states that, based on the observations reported, no significant treatment-related toxicity or adverse effects were identified among the study subjects, other than a reported issue regarding discomfort associated with swallowing the relatively large capsules.
Limitations of the Observations
The Company cautions investors that the study was a small, preliminary clinical observation involving only ten subjects and was not a randomized, blinded or placebo-controlled clinical trial.
In addition, the subjects had heterogeneous diseases, stages of disease, underlying conditions and treatment histories. The subjects with solid tumors also received other therapeutic interventions, including chemotherapy, radiation therapy, surgery and/or targeted therapies. These factors substantially limit the ability to determine whether any observed clinical changes were caused by the ion-modified peptide products.
1
The hospital report itself acknowledges that the use of concurrent or prior cancer therapies limits the ability to independently evaluate the effect of the ion-modified peptide products based on changes in tumor morphology observed through imaging.
Accordingly, the observations described in the report should not be interpreted as establishing the safety or efficacy of AX-3, PPY-3 or any other Company product for the diagnosis, treatment, mitigation, cure or prevention of cancer or any other disease. Additional research, including appropriately designed controlled clinical studies, would be required to evaluate safety and efficacy.
The Company views the hospital report as preliminary observational information that may assist the Company in evaluating potential future research and development activities relating to its ion-modified peptide technology.
Copies of the hospital’s clinical observation report and the accompanying patient observation tables are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.
The Company will continue to evaluate the results of the observation study and potential next steps. There can be no assurance that these observations will be replicated in additional studies, that future studies will produce favorable results, or that any product based on the Company’s ion-modified peptide technology will receive regulatory approval or be successfully commercialized.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements, including statements concerning the Company’s evaluation of the clinical observation results, potential future research and development activities, additional studies, regulatory activities and the potential development or commercialization of products utilizing ion-modified peptide technology. Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such statements.
Such risks and uncertainties include, among others, the preliminary and observational nature of the reported results; the small number and heterogeneous characteristics of the subjects; the absence of a randomized control group; the use of concurrent or prior therapies; the Company’s ability to reproduce or validate the reported observations in larger and appropriately controlled studies; the risks and uncertainties inherent in product development and clinical research; regulatory requirements applicable to the Company’s products and activities; and the other risks described in the Company’s filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Zhejiang Kangjing Hospital Clinical Observation Study Report Regarding Ion-Modified Peptide Adjunctive Treatment | |
| 99.2 | Patient Observation Data Tables Relating to Ion-Modified Peptide Adjunctive Treatment | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
Date: August 24, 2026
| AMERICA GREAT HEALTH | ||
| By: | /s/ Mike Wang | |
| Name: | Mike Wang | |
| Title: | President | |
3
Exhibit 99.1
Zhejiang Kangjing Hospital
Clinical Trial Report
Evaluation
of a Clinical Observational Study of Ion-Modified Peptides
as Adjunctive Therapy for Solid Tumors
| Study period | Document status |
| December 2024–May 2026 | Interim Summary |
I. Investigational Products, Methods, and Dosages
A. Investigational products
AX-3 (Ion Peptide No. 1) and PPY-3 (Ion Peptide No. 4).
B. Methods and dosages
Patients with tumors: Four PPY-3 capsules (Ion Peptide No. 4) after breakfast and four AX-3 capsules (Ion Peptide No. 1) after dinner.
Patients with inflammatory disease (bronchiectasis with inflammation): Three AX-3 capsules (Ion Peptide No. 1) after breakfast and after dinner.
II. Description of the 10 Selected Participants
Ten participants were selected for the clinical observational study of ion-modified peptides as adjunctive therapy, as shown in Table 1.
A. General information
| 1. | Age and sex: Eight participants had solid tumors and ranged from 23 to 81 years of age (six men and two women). One 34-year-old woman had a hematologic malignancy—malignant lymphoma. One 39-year-old woman had an inflammatory condition—bronchiectasis with hemoptysis. |
| 2. | Tumor types: The eight solid-tumor cases comprised five cases of lung cancer, including lung cancer with mediastinal, brain, or intrapulmonary metastases; two cases of rectal cancer; and one case of liver cancer. |
| 3. | Comorbidities: Among the eight participants with solid tumors, three had chronic obstructive pulmonary disease (COPD) with respiratory failure, one had obstructive pneumonia, and one had diabetes. The remaining three had no complications other than the diagnosed tumor. |
| 4. | Deaths among participants with tumors: A 65-year-old man with advanced liver cancer and respiratory failure died after 25 days of treatment. An 81-year-old man with rectal cancer with lung metastasis, diabetes, and COPD died after 22 days of treatment. Both participants withdrew from the clinical observational study of ion-modified peptide adjunctive therapy. |
B. Two participants with other diseases
| 5. | Malignant lymphoma: A 34-year-old woman diagnosed with malignant lymphoma participated in and completed the clinical observational study of ion-modified peptide adjunctive therapy. |
| 6. | Bronchiectasis: A 39-year-old woman diagnosed with bronchiectasis with hemoptysis participated in and completed the clinical observational study of ion-modified peptide adjunctive therapy. |
C. Summary Evaluation of the Clinical Observational Study
1. Role of ion-modified peptides added to standard antitumor therapy
All eight selected participants with solid tumors received combination treatment. Each had undergone radiotherapy, chemotherapy, or surgery. Outcomes following the addition of ion-modified peptide adjunctive therapy were considered acceptable.
Representative Case 1: Mr. Wu Junbo, a 23-year-old man, was diagnosed with lung cancer with a solitary brain metastasis. He received a single session of CyberKnife radiosurgery to the brain metastatic lesion (24 Gy per session). He did not receive chemotherapy, interventional treatment, or other surgery; however, he had received osimertinib targeted therapy for more than three years. Ion-modified peptide adjunctive therapy was added to this treatment, with a reported marked therapeutic response.
Representative Case 2: Mr. Chen Jianzhong, a 71-year-old man, was diagnosed with rectal cancer. After surgery and two cycles of moderate-dose chemotherapy, he received ion-modified peptide adjunctive therapy, with a reported marked therapeutic response.
2. Analysis of the two deaths and withdrawals
Both participants with tumors died from advanced disease complicated by multiple-organ failure. This suggests that future eligibility criteria should exclude patients with malignant tumors accompanied by multiple-organ failure. Otherwise, assessment of the effects or efficacy of ion-modified peptide adjunctive therapy in a clinical observational study may be confounded.
3. Clinical observations in malignant lymphoma
The study included one 34-year-old woman diagnosed with malignant lymphoma. During three cycles of chemotherapy for malignant lymphoma, she also received ion-modified peptide adjunctive therapy. Her condition was considered acceptable. Detailed observational data are provided in Tables 1–5.
4. Clinical observations in bronchiectasis
The study included one 39-year-old woman diagnosed with bronchiectasis with hemoptysis. Ion-modified peptide adjunctive therapy was administered together with anti-infective treatment and symptomatic treatment for cough and sputum. The condition was controlled, hemoptysis resolved, and cough and sputum production improved markedly. Overall recovery was considered acceptable. Detailed observational data are provided in Tables 1–5.
5. Limitations of the clinical observational study
The eight participants with solid tumors had received baseline chemotherapy, radiotherapy, surgery, or targeted therapy. Consequently, changes in tumor size assessed by CT or B-mode ultrasonography could not be attributed independently to ion-modified peptide adjunctive therapy with sufficient confidence. No evaluation of this endpoint is therefore provided at this stage; this constitutes a limitation of the clinical observational study. In contrast, observations and assessments of blood biochemistry (including blood lipids), peripheral complete blood counts, immune-cell function, and clinical vital signs may have greater clinical relevance and value.
6. Summary of the safety evaluation
The selected participants received the investigational products (ion-modified peptides) in accordance with the specified doses and methods. As shown in Tables 1–5, no significant changes were observed in peripheral complete blood counts, blood biochemistry and lipid profiles, oxygen saturation, immune-cell measurements, or vital signs, indicating no statistically significant differences. The report therefore concludes that ion-modified peptide adjunctive therapy demonstrated a favorable safety profile and that no toxic or adverse effects were observed among the participants. A small number of patients reported mild discomfort when swallowing because the oral ion-modified peptide capsules were relatively large; consideration should be given to producing smaller capsules in the future.
Project Lead: Hospital Director Hao Jian
Exhibit 99.2
1. Clinical Efficacy of Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. | Name | Sex | Age (years) | Diagnosis | Before Treatment | 1 Month After Treatment | 3 Months After Treatment | 6 Months After Treatment | |||||||
| Respiratory | Gastrointestinal | Respiratory | Gastrointestinal | Respiratory | Gastrointestinal | Respiratory | Gastrointestinal | ||||||||
| 1 | Wu Junbo | Male | 23 | Lung cancer with brain metastasis | Irritative choking cough, dyspnea, and chest tightness | None | Irritative choking cough, dyspnea, and chest tightness resolved | None | No chest tightness or dyspnea; no cough or sputum production. | None | No chest tightness or dyspnea; no cough or sputum production. | None | |||
| 2 | Jin Deshui | Male | 72 | Lung cancer with mediastinal metastasis | Mild cough and sputum production, accompanied by chest tightness and discomfort. | None | Cough resolved; slight sputum production remained; chest tightness and discomfort resolved. | None | No cough, sputum production, or chest tightness. | None | No cough, sputum production, or chest tightness. | None | |||
| 3 | Chen Jianzhong | Male | 71 | Rectal cancer | None | Mild abdominal pain and distension, with alternating constipation and diarrhea. | None | Mild abdominal pain and distension improved; no alternating constipation and diarrhea. | None | No abdominal pain or distension; no constipation or diarrhea. | None | No abdominal pain or distension; no constipation or diarrhea. | |||
| 4 | Liu Quandang | Male | 78 | Advanced lung cancer and advanced COPD | Marked cough and sputum production, with pronounced dyspnea, chest tightness, and palpitations. | None | Mild cough and moderate sputum production; dyspnea and chest tightness improved; palpitations resolved. | None | Mild cough and sputum production; dyspnea and chest tightness improved; no palpitations. | None | Mild cough and sputum production; dyspnea and chest tightness improved. | None | |||
| 5 | Chen Jiangna | Female | 34 | Malignant lymphoma | No cough or sputum production; chest tightness and palpitations, accompanied by low- to moderate-grade fever. | Mild abdominal distension, no diarrhea, and poor appetite. | No obvious respiratory symptoms, but chest tightness and palpitations were present, with irregular low- to moderate-grade fever. | Mild abdominal distension, no diarrhea, and poor appetite. | Chest tightness and palpitations persisted, as did irregular low- to moderate-grade fever. | Abdominal distension decreased; no diarrhea; poor appetite. | Chest tightness and palpitations persisted, with irregular low-grade fever. | Mild abdominal distension, no diarrhea, and poor appetite. | |||
| 6 | Zhang Haixiang | Female | 58 | Left upper-lobe lung cancer with obstructive pneumonia | Moderate-grade fever and marked cough with sputum production, accompanied by dyspnea and chest tightness; no palpitations. | None | Occasional low-grade fever; cough and sputum production decreased, with dyspnea and chest tightness. | None | No fever; mild cough without sputum production; dyspnea and chest tightness persisted. | None | No fever, cough, or sputum production; dyspnea and chest tightness improved. | None | |||
| 7 | Zhao Pingni | Female | 64 | Diffuse lung cancer | Marked cough and sputum production, with dyspnea and palpitations. | None | Predominantly cough and dyspnea, accompanied by palpitations, chest tightness, and fatigue. | None | Cough and dyspnea remained predominant; accompanying palpitations, chest tightness, and fatigue improved. | None | Cough and dyspnea decreased; palpitations and chest tightness persisted; no fatigue. | None | |||
| 8 | Zhang Chun | Male | 65 | Advanced liver cancer with respiratory failure | Advanced liver cancer with extensive lung metastases, causing extreme dyspnea and respiratory failure. | Massive ascites with abdominal distension and pain; cachectic state. | Extreme dyspnea further worsened; respiratory failure accompanied by heart failure. | Massive ascites progressively worsened, with persistent abdominal distension and pain; cachexia worsened. | Deceased | ||||||
| 9 | Zhao Pingxiao | Male | 81 | Rectal cancer with lung metastasis, diabetes, and COPD | Marked cough and sputum production with severe shortness of breath and dyspnea, cyanotic lips, and respiratory failure. | Persistent marked abdominal distension and pain, pronounced poor appetite, and constipation. | Shortness of breath and dyspnea with extreme breathing difficulty and respiratory failure. | Persistent marked abdominal distension and pain with massive ascites; extremely poor appetite and almost no food intake. | Deceased | ||||||
| 10 | Gao Jun | Female | 39 | Bronchiectasis | Marked cough and sputum production; expectoration of bright-red blood, approximately 50 mL/day, with chest tightness, fatigue, and shortness of breath. | None | Cough and sputum production markedly decreased; no hemoptysis; chest tightness, shortness of breath, and fatigue remained. | None | Cough persisted; no sputum production or hemoptysis; chest tightness and fatigue, but no shortness of breath. | None | Occasional cough; no sputum production, hemoptysis, shortness of breath, chest tightness, or fatigue. | None | |||
2. Changes in Vital Signs During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. | Name | Sex | Age (years) | Diagnosis | Before Treatment | 1 Month After Treatment | 3 Months After Treatment | 6 Months After Treatment | |||||||||||||||||||
| Respiratory Rate (breaths/min) | Pulse (beats/min) | Heart Rate (beats/min) | Oxygen Saturation (SO2%) | Blood Pressure (mmHg) | Respiratory Rate (breaths/min) | Pulse (beats/min) | Heart Rate (beats/min) | SO2 (%) | Blood Pressure (mmHg) | Respiratory Rate (breaths/min) | Pulse (beats/min) | Heart Rate (beats/min) | SO2 (%) | Blood Pressure (mmHg) | Respiratory Rate (breaths/min) | Pulse (beats/min) | Heart Rate (beats/min) | SO2 (%) | Blood Pressure (mmHg) | ||||||||
| 1 | Wu Junbo | Male | 23 | Lung cancer with brain metastasis | 22 | 72 | 72 | 98 | 126/78 | 21 | 68 | 81 | 99 | 120/72 | 24 | 68 | 70 | 99 | 122/72 | 20 | 66 | 66 | 100 | 118/70 | |||
| 2 | Jin Deshui | Male | 72 | Lung cancer with mediastinal metastasis | 21 | 84 | 84 | 95 | 138/88 | 24 | 90 | 81 | 94 | 140/78 | 26 | 80 | 80 | 95 | 129/78 | 22 | 78 | 77 | 94 | 139/85 | |||
| 3 | Chen Jianzhong | Male | 71 | Rectal cancer | 24 | 82 | 82 | 98 | 140/86 | 19 | 77 | 78 | 98 | 138/76 | 22 | 76 | 77 | 97 | 134/84 | 24 | 74 | 74 | 98 | 140/88 | |||
| 4 | Liu Quandang | Male | 78 | Advanced lung cancer and advanced COPD | 28 | 90 | 90 | 91 | 145/92 | 29 | 94 | 94 | 93 | 150/90 | 30 | 85 | 84 | 92 | 138/88 | 26 | 82 | 81 | 93 | 140/78 | |||
| 5 | Chen Jiangna | Female | 34 | Malignant lymphoma | 26 | 86 | 86 | 96 | 138/87 | 30 | 91 | 91 | 96 | 138/82 | 24 | 80 | 78 | 97 | 127/77 | 20 | 82 | 84 | 96 | 136/82 | |||
| 6 | Zhang Haixiang | Female | 58 | Left upper-lobe lung cancer with obstructive pneumonia | 28 | 90 | 90 | 96 | 150/90 | 27 | 94 | 94 | 92 | 146/94 | 24 | 88 | 86 | 92 | 142/84 | 22 | 84 | 83 | 93 | 138/82 | |||
| 7 | Zhao Pingni | Female | 64 | Diffuse lung cancer | 27 | 78 | 78 | 92 | 146/87 | 30 | 84 | 84 | 94 | 142/90 | 22 | 72 | 72 | 95 | 136/82 | 23 | 70 | 69 | 94 | 142/87 | |||
| 8 | Zhang Chun | Male | 65 | Advanced liver cancer with respiratory failure | 32 | 102 | 114 | 89 | 152/100 | 34 | 87 | 88 | 78 | 156/96 | Deceased | ||||||||||||
| 9 | Zhao Pingxiao | Male | 81 | Rectal cancer with lung metastasis, diabetes, and COPD | 34 | 111 | 111 | 90 | 149/96 | 36 | 99 | 105 | 74 | 149/96 | Deceased | ||||||||||||
| 10 | Gao Jun | Female | 39 | Bronchiectasis | 26 | 80 | 80 | 128/78 | 26 | 80 | 80 | 99 | 128/78 | 22 | 78 | 78 | 98 | 136/82 | 20 | 72 | 70 | 100 | 130/74 | ||||
2
3. Changes in Peripheral Blood Counts During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. | Name | Sex | Age (years) | Diagnosis | Before Treatment | 1 Month After Treatment | 3 Months After Treatment | 6 Months After Treatment | |||||||||||
| WBC (×10⁹/L) | Neutrophils (%) | Lymphocytes (%) | WBC (×10⁹/L) | Neutrophils (%) | Lymphocytes (%) | WBC (×10⁹/L) | Neutrophils (%) | Lymphocytes (%) | WBC (×10⁹/L) | Neutrophils (%) | Lymphocytes (%) | ||||||||
| 1 | Wu Junbo | Male | 23 | Lung cancer with brain metastasis | 5.8 | 58.1 | 21.4 | 6.1 | 64.3 | 32.1 | 6.4 | 59.8 | 33.3 | 5.8 | 61.4 | 31.8 | |||
| 2 | Jin Deshui | Male | 72 | Lung cancer with mediastinal metastasis | 6.1 | 68.3 | 24.3 | 7.5 | 62.8 | 32.1 | 7.2 | 58.2 | 27.4 | 6.8 | 69.7 | 21.1 | |||
| 3 | Chen Jianzhong | Male | 71 | Rectal cancer | 7.4 | 70.8 | 24.1 | 6.7 | 64.2 | 31.2 | 5.8 | 66.3 | 27.6 | 5.3 | 56.8 | 33.2 | |||
| 4 | Liu Quandang | Male | 78 | Advanced lung cancer and advanced COPD | 9.5 | 80.4 | 12.2 | 6.2 | 72.1 | 22.7 | 6.2 | 78.1 | 20.5 | 5.9 | 70.5 | 27.5 | |||
| 5 | Chen Jiangna | Female | 34 | Malignant lymphoma | 8.9 | 28.3 | 62.6 | 9.6 | 25.9 | 65.9 | 8.3 | 24.7 | 66.3 | 8.1 | 23.4 | 65.2 | |||
| 6 | Zhang Haixiang | Female | 58 | Left upper-lobe lung cancer with obstructive pneumonia | 10.2 | 85.8 | 10.5 | 8.5 | 73.2 | 20.7 | 7.5 | 68.7 | 28.5 | 6.4 | 65.1 | 30.3 | |||
| 7 | Zhao Pingni | Female | 64 | Diffuse lung cancer | 12.3 | 82.3 | 11.2 | 8.2 | 70.5 | 23.7 | 6.5 | 67.4 | 31.4 | 7.6 | 70.2 | 29.5 | |||
| 8 | Zhang Chun | Male | 65 | Advanced liver cancer with respiratory failure | 11.2 | 88.1 | 9.4 | 13.4 | 90.5 | 8.7 | Deceased | ||||||||
| 9 | Zhao Pingxiao | Male | 81 | Rectal cancer with lung metastasis, diabetes, and COPD | 14.2 | 90.2 | 8.7 | 18.7 | 91.6 | 7.1 | Deceased | ||||||||
| 10 | Gao Jun | Female | 39 | Bronchiectasis | 8.1 | 56.5 | 23.7 | 6.9 | 59.8 | 29.1 | 5.7 | 56.2 | 30.2 | 6.1 | 57.2 | 27.9 | |||
3
4. Changes in Lipid Profile During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors (Unit: mol/L)
| No. | Name | Sex | Age (years) | Diagnosis | Before Treatment | 1 Month After Treatment | 3 Months After Treatment | 6 Months After Treatment | |||||||||||||||
| Total Cholesterol (TC) | Triglycerides (TG) | HDL Cholesterol (HDL-C) | LDL Cholesterol (LDL-C) | TC | TG | HDL-C | LDL-C | TC | TG | HDL-C | LDL-C | TC | TG | HDL-C | LDL-C | ||||||||
| 1 | Wu Junbo | Male | 23 | Lung cancer with brain metastasis | 4.2 | 1.5 | 2.3 | 2.9 | 3.8 | 1.6 | 2.0 | 3.2 | 5.2 | 1.2 | 1.8 | 2.8 | 4.8 | 1.6 | 3.2 | 2.3 | |||
| 2 | Jin Deshui | Male | 72 | Lung cancer with mediastinal metastasis | 3.8 | 2.3 | 1.1 | 3.1 | 4.1 | 2.8 | 1.4 | 2.9 | 4.9 | 1.8 | 2.0 | 3.2 | 5.1 | 2.1 | 3.6 | 2.7 | |||
| 3 | Chen Jianzhong | Male | 71 | Rectal cancer | 4.4 | 2.6 | 1.4 | 2.9 | 3.8 | 2.2 | 1.6 | 3.3 | 4.6 | 1.7 | 1.7 | 3.5 | 4.9 | 2.3 | 2.5 | 3.1 | |||
| 4 | Liu Quandang | Male | 78 | Advanced lung cancer and advanced COPD | 5.0 | 1.8 | 1.6 | 3.8 | 4.8 | 2.4 | 1.3 | 4.2 | 5.0 | 2.1 | 1.9 | 3.8 | 3.9 | 1.8 | 2.4 | 3.2 | |||
| 5 | Chen Jiangna | Female | 34 | Malignant lymphoma | 3.4 | 2.1 | 1.4 | 2.7 | 3.5 | 3.1 | 1.7 | 3.1 | 5.3 | 2.3 | 2.1 | 3.4 | 5.2 | 1.9 | 2.6 | 2.9 | |||
| 6 | Zhang Haixiang | Female | 58 | Left upper-lobe lung cancer with obstructive pneumonia | 5.6 | 1.7 | 1.7 | 2.5 | 4.9 | 1.6 | 1.5 | 3.3 | 4.8 | 1.8 | 1.7 | 4.0 | 5.0 | 1.6 | 2.9 | 3.7 | |||
| 7 | Zhao Pingni | Female | 64 | Diffuse lung cancer | 3.4 | 2.2 | 1.2 | 2.7 | 3.1 | 1.8 | 1.7 | 2.9 | 5.3 | 2.2 | 2.0 | 3.5 | 5.5 | 2.4 | 2.2 | 4.1 | |||
| 8 | Zhang Chun | Male | 65 | Advanced liver cancer with respiratory failure | 6.1 | 3.1 | 1.0 | 4.1 | 7.4 | 2.9 | 1.2 | 5.1 | Deceased | ||||||||||
| 9 | Zhao Pingxiao | Male | 81 | Rectal cancer with lung metastasis, diabetes, and COPD | 2.8 | 1.4 | 1.5 | 4.4 | 2.6 | 1.6 | 1.2 | 5.8 | Deceased | ||||||||||
| 10 | Gao Jun | Female | 39 | Bronchiectasis | 4.5 | 1.6 | 1.6 | 3.1 | 3.9 | 1.7 | 2.1 | 2.9 | 4.5 | 1.7 | 2.1 | 2.9 | 3.9 | 1.4 | 1.6 | 3.0 | |||
4
5. Changes in Immune Cells During Ion-Peptide Adjunctive Therapy in Patients with Solid Tumors
| No. | Name | Sex | Age (years) | Diagnosis | Before Treatment (%) | 1 Month After Treatment (%) | 3 Months After Treatment (%) | 6 Months After Treatment (%) | |||||||
| CD3+CD8⁺ | CD16+CD56⁺ | CD3+CD8⁺ | CD16+CD56⁺ | CD3+CD8⁺ | CD16+CD56⁺ | CD3+CD8⁺ | CD16+CD56⁺ | ||||||||
| 1 | Wu Junbo | Male | 23 | Lung cancer with brain metastasis | 79.83 | 16.94 | 32.33 | 48.30 | 26.32 | 88.58 | 83.44 | 79.98 | |||
| 2 | Jin Deshui | Male | 72 | Lung cancer with mediastinal metastasis | 57.11 | 25.36 | 66.34 | 72.71 | 42.29 | 63.81 | 64.77 | 78.31 | |||
| 3 | Chen Jianzhong | Male | 71 | Rectal cancer | 39.12 | 12.22 | 79.37 | 79.28 | 65.18 | 74.11 | 48.07 | 88.93 | |||
| 4 | Liu Quandang | Male | 78 | Advanced lung cancer and advanced COPD | 44.23 | 65.27 | 62.79 | 24.45 | 77.25 | 74.36 | 20.07 | 33.41 | |||
| 5 | Chen Jiangna | Female | 34 | Malignant lymphoma | 63.88 | 24.82 | 38.61 | 57.26 | 72.51 | 76.53 | 59.31 | 53.14 | |||
| 6 | Zhang Haixiang | Female | 58 | Left upper-lobe lung cancer with obstructive pneumonia | 34.08 | 58.36 | 68.34 | 65.66 | 75.89 | 45.27 | 54.23 | 81.37 | |||
| 7 | Zhao Pingni | Female | 64 | Diffuse lung cancer | 54.08 | 31.72 | 80.64 | 84.49 | 62.84 | 76.76 | 46.03 | 79.01 | |||
| 8 | Zhang Chun | Male | 65 | Advanced liver cancer with respiratory failure | 16.49 | 18.58 | 17.99 | 5.39 | Deceased | ||||||
| 9 | Zhao Pingxiao | Male | 81 | Rectal cancer with lung metastasis, diabetes, and COPD | 14.33 | 12.97 | 13.48 | 9.61 | Deceased | ||||||
| 10 | Gao Jun | Female | 39 | Bronchiectasis | 79.83 | 36.94 | 71.29 | 13.06 | 58.46 | 87.15 | 63.54 | 76.48 | |||
5